• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy

    2022-06-29 01:46:56WanTingCaoRongHuangShanLiuYiHongFanMaoShengXuYiXuHuiNi
    World Journal of Gastroenterology 2022年23期

    Wan-Ting Cao,Rong Huang, Shan Liu,Yi-Hong Fan,Mao-Sheng Xu, Yi Xu,Hui Ni

    Abstract

    Key Words: Infliximab trough level; C-reactive protein; Fecal calprotectin; Crohn’s disease; Clinical remission; Long-term endoscopic outcomes

    INTRODUCTION

    Crohn’s disease (CD) is a persistently progressive disease with nonspecific inflammation characterized by disease scope involving the whole digestive tract and disease depth involving the whole intestinal wall. The accumulation damage of intestinal walls contributes to the occurrence of stenosis, fistula and even abscess, reducing the life quality. Therefore, recent clinical studies have consistently concluded that therapeutic strategies and targets play key roles in controlling CD progression. Setting different therapeutic targets will have different disease outcomes. Clinical response, focusing only on the improvement of clinical symptoms, can improve the quality of daily life but not affect long-term treatment outcomes. CD patients who do not achieve deep remission may be aggravated persistently,while achieving deep remission could reduce long-term hospitalization and surgery rates. Deep remission is mainly defined in previous studies as endoscopic remission or mucosal healing. Biologics,as an important step in the therapeutic strategy of CD, can effectively control the disease progression if conducted early and completely.

    In consideration of the wide use of infliximab (IFX), precisely predicting the long-term endoscopic outcomes is stressed by more and more inflammatory bowel disease (IBD) physicians. Although the IFX trough level (ITL) has been proven to be closely related to the outcome of CD, ITL alone may be biased in predicting the outcome of CD. Monitoring inflammation biomarkers is one of the important links of IFX therapy, including C-reaction protein (CRP), fecal calprotectin (FCP),etc.High inflammatory load affects the pharmacokinetics of IFX, inducing secondary nonresponse by decreasing blood drug concentration. Currently, it is believed that inflammatory biomarkers are good predictors of disease activity,but there is still a lack of reliable evidence for predicting disease remission. Therefore, this study intends to evaluate long-term endoscopic outcomes of CD patients receiving IFX treatment by combining the blood drug concentration and inflammatory biomarkers.

    MATERIALS AND METHODS

    Study subjects design

    A single-center retrospective research was implemented at the First Affiliated Hospital of Zhejiang Chinese Medical University. CD patients under IFX therapy from January 2012 to December 2020 were collected. One hundred and eighty-one CD patients underwent IFX treatment. One hundred and fiftyone CD patients underwent endoscopy as well as serum concentration monitoring at week 14 after the third dose of IFX induction therapy. Inclusion criteria: (1) Endoscopic remission at week 14 [Crohn’s disease endoscopic index of severity (CDEIS) score ≤ 2 points or Rutgeerts ≤ i1]; (2) Clinical remission after IFX induction therapy without corticosteroids more than 6 mo; and (3) Therapeutic strategy during maintenance stage was designed as IFX 5 mg/kg every 8 wk combined with azathioprine (AZA) 50 mg every day. Therapeutic strategic was modulated if CD patients were confronted with clinical relapse or secondary loss of response (LOR), and data analysis focused on the treatment course when patients received IFX 5 mg/kg and AZA therapy regularly. Secondary LOR was defined as a recurrence of the disease during IFX maintenance therapy. Two criteria were met to determine LOR: The recurrence of symptoms of IBD in clinical remission after induction therapy and symptoms caused by the inflammatory activity of IBD itself. Clinical relapse means Crohn’s disease activity index > 150 points. Blood drug concentration monitoring and clinical, laboratory, endoscopic and imaging evaluation were implemented every 2 mo since the third dose of IFX induction therapy in all patients. The study was divided into two stages, step I study period defined as IFX maintenance therapy during week 14 to week 54 and step II study period defined as IFX maintenance therapy during week 54 to week 108.

    Data collection

    General data included age, sex, course, disease location, disease behavior, medication history and history of intestinal surgery. Laboratory indicators include white blood cell count, blood platelet count,CRP, erythrocyte sedimentation rate, serum albumin, FCP, ITL and anti-IFX antibody. Evaluation indicators of disease severity included Crohn’s disease activity index score on clinical severity, CDEIS score on endoscopic severity in CD patients without intestinal surgery and Rutgeerts score on endoscopic severity in CD patients with intestinal surgery.

    Outcome definition

    Endoscopic outcomes at week 54 and week 108 after IFX initial therapy were evaluated by specialist physicians on IBD under electronic colonoscopy. Endoscopic remission was defined as CDEIS score ≤ 2 or Rutgeerts score ≤ i1, and endoscopic activity was defined as CDEIS score > 2 or Rutgeerts score > i1.Survival outcomes during IFX maintenance therapy were concentrated on endoscopic relapse-free survival, defined as sustained endoscopic remission during step I study period or step II study period.

    Statistical analysis

    Descriptive statistical analysis was used to describe characteristics of CD patients. Number of cases(percentage) was used to describe categorial variable. mean ± SD was used to describe continuous variable. Nonparametric Mann-Whitney test was used to compare two groups in enumeration data or measurement data without normal distribution. Two-sample t test was used to compare two groups in measurement data with normal distribution. One-way analysis of variance was used to compare multigroup if data satisfied homogeneity of variance. Nonparametric Kruskal-Wallis test was used to compare multi-group if data not satisfied homogeneity of variance. SPSS 23.0 (Armonk, NY, United States) was used to analyze differences between groups. APvalue < 0.05 was considered significant.

    Receiver-operating characteristic (ROC) analysis was used to identify the best cut off level of ITL on predicting endoscopic remission as well as sensitivity, specificity, positive predictive value, negative predictive value, area under the curve and Youden Index. Univariate logistic regression analysis was used to identify the association between endoscopic activity and predictors. Log-rank test was used to identify the association between endoscopic relapse and predictors. GraphPad Prism9.0 (San Diego, CA,United States) was used to draw histograms and survival analysis curves and implement log-rank test.MedCalc19.0 was used to draw ROC curve and analyze the predictive value of indicators on endoscopic outcomes. APvalue < 0.05 was considered significant.

    RESULTS

    Characteristics of study subjects

    In total, the study cohort collected 112 CD patients achieving clinical remission after IFX induction therapy. In step I study, 19 CD patients were excluded due to data absence (n= 1, 5.26%) and endoscopic activity at week 14 (n= 18, 94.74%), while 93 CD patients with endoscopic remission at week 14 were included. In step II study, 58 CD patients were excluded due to course of therapy shorter than 2 years (n= 10, 17.24%), secondary non-response of IFX (n= 12, 20.69%), suspension of IFX therapy within 2 years for disease remission (n= 10, 17.24%) and endoscopic activity at week 54 (n= 26, 44.83%), while 54 CD patients with endoscopic remission at week 54 were included. These 12 patients did not satisfy indications of operation and received hormonotherapy as the primary choice to alleviate disease, for our center lacked other biological agents at that time. All CD patients under IFX maintenance therapy were combined with AZA (Figure 1). The dose of IFX was 5 mg/kg every 8 wk, and the dose of AZA was 50 mg every day. Characteristics of CD patients included in study are shown in Table 1.

    Correlation between ITL, inflammatory biomarkers and endoscopic outcomes

    In step I study, 67/93 CD patients (72.04%) sustained endoscopic remission at week 54 among.Multivariable regression analysis revealed that only ITL (OR = 0.666, 95%CI: 0.514-0.862,P= 0.002) and FCP (OR = 1.002, 95%CI: 1.001-1.004,P= 0.002) were independent risk of endoscopic activity at week 54(Table 2). Based on incremental gain analysis, an ITL range of 5.0-7.4 μg/mL was correlated with sustained endoscopic remission rate of more than 85% (Figure 2).

    In step II study, 42/54 CD patients (77.78%) sustained endoscopic remission at week 108.Multivariable regression analysis revealed that only ITL (OR = 0.466, 95%CI: 0.247-0.877,P= 0.018) and CRP (OR = 1.590, 95%CI: 1.007-2.510,P= 0.047) were independent risks of endoscopic activity at week 108 (Table 2). Based on incremental gain analysis, an ITL range of 2.0-3.9 μg/mL was correlated with sustained endoscopic remission rate of more than 85% (Figure 2).

    Predictive value of ITL and inflammatory biomarkers on endoscopic outcomes

    In step I study, the ROC analysis demonstrated that the best cut off level of ITL and FCP at week 14 on predicting endoscopic relapse at week 54 was 5.60 μg/ml (AUC = 0.83, 95%CI: 0.73-0.90, P < 0.001) and 238 μg/g (AUC = 0.82, 95%CI: 0.72-0.89, P < 0.001) (Table 3 and Figure 3). CD patients with ITL ≤ 5.60 μg/ml and FCP > 238 μg/g at week 14 had 82% probability of endoscopic relapse at week 54. However,CD patients with ITL > 5.60 μg/ml and FCP ≤ 238 μg/g at week 14 had 98% probability of sustained endoscopic remission at week 54.

    In step II study, the ROC analysis demonstrated that the best cut off level of ITL and CRP at week 54 on predicting endoscopic relapse at week 108 was 2.10 μg/mL (AUC = 0.85, 95%CI: 0.72-0.93,P< 0.001)and 3.00 mg/L (AUC = 0.73, 95%CI: 0.60-0.84,P= 0.012) (Table 3 and Figure 3). CD patients with ITL ≤2.10 μg/mL and CRP > 3.00 mg/L at week 54 had 100% probability of endoscopic relapse at week 108.However, CD patients with ITL > 2.10 μg/mL and CRP ≤ 3.00 mg/L at week 54 had 97% probability of sustained endoscopic remission at week 108.

    Correlation between ITL, inflammatory biomarkers and endoscopic relapse-free survival

    In step I study, 26/93 (27.96%) CD patients had experienced endoscopic relapse from week 14 to week 54 of IFX maintenance therapy. The estimated endoscopic relapse-free rate was 46/48 (95.83%) in CD patients with ITL > 5.6 μg/ml and 21/45 (46.67%) in CD patients with ITL ≤ 5.6 μg/ml. The median time to endoscopic relapse of CD patients with ITL ≤ 5.6 μg/ml was 32.00 wk shorter than those with ITL >5.6 μg/ml [hazard ratio (HR) = 16.19, 95%CI: 7.44-35.22, P < 0.0001] (Figure 4A). The estimated endoscopic relapse-free rate was 6/25 (24.00%) in CD patients with FCP > 238 μg/g and 61/68 (89.71%)in CD patients with FCP ≤ 238 μg/g. The median time to endoscopic relapse of CD patients with FCP >238 μg/g was 21.00 wk shorter than those with FCP ≤ 238 μg/g (HR = 11.25, 95%CI: 4.26-29.73, P <0.0001) (Figure 4B).

    Table 1 Clinical characteristics of Crohn‘s disease patients with endoscopic remission

    In step II study, 12/54 (22.22%) CD patients had experienced endoscopic relapse from week 54 to week 108 of IFX maintenance therapy. The estimated endoscopic relapse-free rate was 38/41 (92.68%) in CD patients with ITL > 2.1 μg/mL and 4/13 (30.77%) in CD patients with ITL ≤ 2.1 μg/mL. The median time to endoscopic relapse of CD patients with ITL ≤ 2.1 μg/mL was 40.00 w, shorter than those with ITL > 2.1 μg/mL (HR = 13.14, 95%CI: 3.07-56.27,P< 0.0001) (Figure 4D). The estimated endoscopic relapse-free rate was 4/8 (50.00%) in CD patients with CRP > 3.00 mg/L and 40/46 (86.96%) in CD patients with CRP ≤ 3.00 mg/L. The median time to endoscopic relapse of CD patients with CRP > 3.00 mg/L was 50.00 wk shorter than those with CRP ≤ 3.00 mg/L (HR = 7.85, 95%CI: 1.31-46.85,P< 0.0001)(Figure 4C).

    DISCUSSION

    Several studies have confirmed that different ITLs brought about different outcomes of CD under IFX therapy (Table 4). Tanget al[1] discovered that CD patients achieving mucosal healing at week 14 of IFXtherapy with ITL > 2.5 μg/mL at week 14 had 71% chance of mucosal healing at week 54, while patients with ITL < 2.5 μg/mL had only 33% chance. ITL ≥ 3 μg/mL at the beginning of IFX maintenance therapy was confirmed as a predictor of sustained response to IFX in CD patients[2]. Recently a prospective study in Japan verified that CD patients with ITL ≥ 3 μg/mL at week 14 after IFX initial therapy had much better long-term clinical outcomes than patients with ITL < 3 μg/mL, of which survival analysis indicated 100% probability of clinical remission at week 108 in the former and 33.3%probability in the latter[3]. A meta-analysis determined that ITL > 2.0 μg/mL of IBD patients under IFX maintenance therapy contributes to better prognosis such as clinical remission or mucosal healing[4].Similarly, this study found that CD patients with ITL > 5.6 μg/mL at week 14 had a large chance ofachieving sustained endoscopic remission during IFX maintenance therapy as well as CD patients with ITL > 2.1 μg/mL at week 54. Borrenet al[5] implemented a multi-center retrospective study and concluded that low ITL in IBD patients during IFX maintenance therapy could not be a good predictor of clinical relapse in the next 2 years, suggesting that proactive therapeutic drug monitoring was not suitable in this group. However, this study discovered that CD patients with ITL ≤ 5.6 μg/mL at week 14 or ITL ≤ 2.1 μg/mL at week 54 were more likely to experience endoscopic relapse during the 1-year follow-up period.

    Table 2 Predictive indicators of endoscopic relapse in Crohn's disease patients with endoscopic remission

    Table 3 Predictive value of indicators on endoscopic relapse

    Figure 1 Patients selected and outcome of infliximab therapy. CD: Crohn‘s disease; EA: Endoscopic activity; IFX: Infliximab.

    Table 4 Previous research of infliximab trough level on deep remission in inflammatory bowel disease

    Figure 2 Incremental gain analysis of sustained endoscopic remission rate in relation to infliximab trough level at week 14 and week 54.

    According to previous studies, the challenge for IBD physicians is to frame the more suitable blood trough level of IFX to achieve better disease prognosis in clinical therapy. The elements associated with the blood trough level of IFX can be classified into three areas. Above all, the better the therapeutic goal desired by IBD physicians or patients, the higher the blood trough level of IFX is required. An observational study contraposing to CD patients with a history of intestinal surgery by Imaedaet al[6] verified that mucosal healing required higher ITLs as more than 4.0 μg/mL compared to those to achieve normalization of routine clinical markers. Papamichaelet al[7] considered that ITL surpassing 9.7 μg/mL indicated 80% probability of endoscopic remission in CD patients under IFX maintenance therapy, while ITL surpassing 2.2 μg/mL was associated only with biochemical remission. Recently, a prospective study verified that ITL > 8.0 μg/mL was highly correlated with histological emission and sustained histological remission in IBD patients[8]. Perianal fistula, the most universal complications of CD patients, is another therapeutic goal. A retrospective cross-sectional study by Plevriset al[9]manifested that perianal fistula healing or closure is associated with higher ITLs as more than 7.1 μg/mL.

    Secondly, each clinical study had different stages of IFX drug monitoring, especially during maintenance therapy. ITL continues to decrease as time passed during IFX maintenance therapy[10]. A cross-sectional study of IBD patients under IFX therapy with a fixed dose more than 6 mo found that IBD patients with ITL ≥ 3.4 μg/mL had a 73% chance of endoscopic mucosal healing[11]. Kanget al[12]showed that ITL ≥ 5 μg/mL during IFX maintenance therapy could identify mucosal healing in pediatric CD patients with 80% specificity. Fenget al[13] innovatively integrated ITL levels in different time stages to identify endoscopic mucosal healing in CD patients, indicating that patients with ITL >4.85 μg/mL at week 14 and ITL > 2.85 μg/mL at week 30 had an 80% chance of achieving endoscopic mucosal healing. Based on incremental gain analysis in our study, sustained endoscopic remission rate at week 54 reached only 54.63% at an ITL range of 2.5 to 4.9 μg/mL at week 14 while corresponding numbers at week 108 was 89.47% at an ITL range of 2.0 to 3.9 μg/mL at week 54. Therefore, the study held the view that CD patients with endoscopic remission need higher ITL at the beginning of IFX maintenance therapy (≥ 5.6 μg/mL at week 14) than after IFX maintenance therapy over a half year (≥2.1 μg/mL at week 54). In addition, CD patients achieving endoscopic remission after IFX induction therapy and sustained endoscopic remission more than a half year may not need high ITL to maintain endoscopic remission.

    Figure 3 Receiver operator characteristic curve of infliximab trough level and inflammatory biomarkers in predicting endoscopic outcomes. A: Receiver operator characteristic (ROC) curve of infliximab trough level at week 14 in predicting endoscopic remission of Crohn’s disease (CD) at week 54; B: ROC curve of fecal calprotectin at week 14 in predicting endoscopic remission of CD at week 54; C: ROC curve of infliximab trough level at week 54 in predicting endoscopic remission of CD at week 108; D: ROC of C-reactive protein at week 54 in predicting endoscopic remission of CD at week 108. ITL: Infliximab trough level; CRP: C-reactive protein; FCP: Fecal calprotectin; AUC: Area under the curve.

    The third element is therapeutic optimization of IFX in IBD. Adverse IFX response as high ATI level or low ITL may occur in a few CD patients during IFX maintenance therapy. Several clinical studies held the view that severe inflammatory activity of CD patients could change pharmacokinetics of antitumor necrosis factor α biology[14-16]. Therapeutic optimization as increasing fixed dose from 5 mg/kg to 10 mg/kg or shortening injection interval form every 8 wk to 4-6 wk contributes to increase ITL and decrease ATI level. A study from Greece demonstrated that, for the initial measurement after therapeutic adjustment, ITL increased from 1.47 μg/mL to 8.50 μg/mL in patients with therapeutic optimization while ITL decreased from 5.65 μg/mL to 3.8μg/ml in patients without therapeutic optimization[10]. A multi-center randomized clinical trial conducted by Dreesenet al[17] showed that CD patients under IFX maintenance therapy as 5 mg/kg had high probability of no mucosal ulcer under endoscopy at week 54 with ITL more than 7.3mg/L, and CD patients under intensified dose IFX therapy as 10 mg/kg had 94% probability of no mucosal ulcer under endoscopy with ITL rising to more than 10.6 mg/L. Therefore, intensified therapy may contribute to mucosal healing in CD patients with ulceration if IFX injection dose is less than 10 mg/kg and ITL is less than 10.6 μg/mL. However, a few CD patients will accept combination therapy of IFX and immunosuppressant to boost the efficacy,especially AZA and mercaptopurine. AZA is a precursor of mercaptopurine, and two components ultimately produce thioguanine to exert clinical effect during metabolism. A study verified that thioguanine concentration more than 125 pmol/8 × 108red blood cells could enhance ITL to 8.3 μg/mL or more and decrease positive rate of ATI[18,19]. Hence, this study mainly included CD patients with sustained clinical remission more than 6 mo under fixed therapeutic strategy of IFX 5 mg/kg every 8 wk combined with AZA 50 mg every day. Retrospective records of CD patients included would suspend if therapy strategy changed, such as intensive therapy of IFX, conversion therapy of other biologics and combination therapy of surgery or other medications. The study design eliminated the influence of therapeutic adjustment on ITL.

    Figure 4 Proportion without endoscopic relapse. A. Time since infliximab (IFX) therapy at week 14 [IFX trough level (ITL) > 5.6 μg/mL vs ITL ≤ 5.6 μg/mL];B: Time to IFX therapy at week 14 (fecal calprotectin ≤ 238 μg/g vs fecal calprotectin > 238 μg/g]; C: Time to IFX therapy at week 54 (C-reactive protein ≤ 3.0mg/L vs C-reactive protein > 3.0 mg/L); D: Time to IFX therapy at week 54 (ITL > 2.1 μg/mL vs ITL ≤ 2.1 μg/mL). ITL: Infliximab trough level; CRP: C-reactive protein; FCP:Fecal calprotectin; IFX: Infliximab.

    The greatest strength of inflammatory biomarkers compared with blood trough level is that they are unaffected by time during different monitoring stages of biological therapy in IBD patients. This study showed that ITL > 5.6 μg/mL combined with FCP ≤ 238 μg/g at week 14 moderately predicted sustained endoscopic remission during the 1-year follow-up period on CD patients with positive predictive value more than 95% as well as ITL > 2.1 μg/mL combined with CRP ≤ 3.00 mg/L at week 54, superior to use ITL as the only predictor. FCP and CRP are considered as the most universal and typical biomarkers of inflammatory evaluation in IBD, also verified to be the independent risk factors of adverse endoscopic outcomes. The study confirmed that combining blood trough level with inflammatory biomarkers contributed to improving the accuracy of the prediction on endoscopic outcomes. A post hoc analysis from the CALM study manifested that CD patients with FCP < 250 μg/g mostly achieved CDEIS < 4 without deep ulceration, regardless of whether CRP < 5 mg/L. However, among patients with CRP < 5 mg/L but FCP ≥ 250 μg/g, only 16.7% achieved CDEIS < 4 without deep ulceration[20]. The result indicated that the correlation between FCP normalization and endoscopic mucosal healing in CD patients was stronger than that of CRP normalization. A previous study verified that FCP is suitable for distinguishing mild endoscopic activity from endoscopic remission, while it is difficult to distinguish partial endoscopic remission from complete endoscopic remission[21]. Similar to blood trough level, the optimal cut off value of FCP for distinguishing endoscopic activity from endoscopic remission ranges from 71 μg/g to 250 μg/g with moderate diagnostic performance[22-27].The study identified that FCP > 276 μg/g predicted endoscopic activity at week 54 of CD patients with clinical remission at week 14 moderately with 84.6% sensitivity and 92.1% specificity. Unlike FCP, the sensitivity of CRP to mild intestinal inflammation was low and the level of CRP increased much more dramatically in CD patients with moderate to severe inflammation. Therefore, the previous study preferred to utilize CRP to distinguish moderate to severe endoscopic activity from mild to moderate endoscopic activity rather than distinguish mild endoscopic activity from endoscopic remission. A Spanish study showed that FCP > 155 μg/g in combination with CRP > 6.7 mg/L could identify endoscopic activity with 82% specificity[27].

    However, the study has shortcomings in some areas. Firstly, the retrospective single-center study with small sample, inferior to prospective multi-center with greater sample, comprised some confounding factors. More real-world studies and randomized controlled trials on guidance significance of ITL to therapeutic outcomes in IBD need to be conducted. Secondly, the study primarily concentrated on mucosal inflammation located in large intestine, ignoring small intestine due to the high cost and the incomplete scoring system of small intestinal evaluation accompanied by the poor compliance of patients and the laborious operation of endoscopists. Correlation between ITL and various small intestinal examinations including endoscopy or imageology may be the focus of the future study. Last but not least, definition of deep remission on CD has been tightened. Considering transmural inflammation of CD, endoscopy is confined to mucosal inflammation and macroscopical evaluation while imageology can accurately evaluate complete volume of intestinal wall and histopathological examination, which contributes to microscopical examination. Notwithstanding endoscopic remission considered as the main targets and histological remission considered as a novel target, the new concept of ‘disease clearance’, which includes clinical, endoscopic and microscopic remission, has drawn more and more attention from IBD physicians and may bring about a new upsurge of studies on IFX monitoring and new therapeutic targets[28].

    CONCLUSION

    In conclusion, during IFX maintenance treatment, low ITL, high CRP level and high FCP level were independent risk factors of long-term adverse endoscopy outcomes in CD patients with clinical remission. Combination of ITL, CRP and FCP contribute to long-term endoscopic prognosis monitoring.The best cut off values of ITL for predicting endoscopic activity within 1-year follow up were 5.60 μg/mL at week 14 and 2.10 μg/mL at week 54. In addition, ITL ≤ 5.60 μg/mL in combination with FCP> 238 μg/g at week 14 as well as ITL ≤ 2.10 μg/mL in combination with CRP > 3.00 mg/L at week 54 increased the precision of prediction on endoscopic outcomes at week 54 and week 108, respectively.Therapeutic optimization is still recommended in CD patients achieving endoscopic remission,provided that low ITLs or high levels of inflammatory biomarkers, such as CRP or FCP, arise to prevent endoscopic recurrence as soon as possible.

    ARTICLE HIGHLIGHTS

    Research conclusions

    The best cut off values of ITL for predicting endoscopic activity within 1-year follow up was 5.60 μg/mL at week 14 and 2.10 μg/mL at week 54. In addition, ITL ≤ 5.60 μg/mL in combination with FCP > 238 μg/g at week 14 as well as ITL ≤ 2.10 μg/mL in combination with CRP > 3.00 mg/L at week 54 increased the precision of prediction on endoscopic outcomes at week 54 and week 108, respectively.

    Research perspectives

    In view of the fact that conduction of intensive monitoring for biological management plays a vital role in precise treatment for CD patients, much larger and more stringent prospective studies are warranted to provide the best predictive models as acknowledged globally in allusion to long-term endoscopic outcomes of CD patients under IFX therapy.

    ACKNOWLEDGEMENTS

    The authors would like to thank Dr. Bin Lv, Full Professor and Chief Physician at the First Affiliated Hospital of Zhejiang Chinese Medical University, Department of Gastroenterology, for his help in revising this paper, and Shan Liu, at the First Affiliated Hospital of Zhejiang Chinese Medical University, Clinical Evaluation Center, for help with statistical analysis.

    FOOTNOTES

    Author contributions:Fan YH designed the research; Cao WT performed the research; Cao WT and Liu S analyzed the data; Cao WT, Huang R, Ni H and Xu MS wrote the paper; Xu Y supervised the paper; All authors have read and approve the final manuscript.

    Supported byNational Natural Science Foundation of China, No. 81473506 and No. 81971600; Zhejiang TCM Science and Technology Project, No. 2019ZA056, No. 2021ZA057 and No. 2016ZA077.

    Institutional review board statement:This study was reviewed and approved by the ethics committee of the First Affiliated Hospital of Zhejiang Chinese Medical University, No. 2021-KL-024-02.

    Informed consent statement:All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

    Conflict-of-interest statement:The authors declare that they have no conflict of interest.

    Data sharing statement:Some or all data, models, or code generated or used during the study are available from the corresponding author by request. People could contact the corresponding author to get the data which is not used for commercial purposes.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:China

    ORCID number:Wan-Ting Cao 0000-0001-7277-4492; Rong Huang 0000-0002-8360-7777; Shan Liu 0000-0001-9139-3257;Yi-Hong Fan 0000-0001-8217-9793; Mao Sheng Xu 0000-0002-2396-1600; Yi Xu 0000-0002-3265-9534; Hui Ni 0000-0001-8973-8834.

    S-Editor:Ma YJ

    L-Editor:Filipodia

    P-Editor:Cai YX

    嫩草影院精品99| 色播亚洲综合网| 欧美激情高清一区二区三区| 久久久国产精品麻豆| 亚洲人成77777在线视频| 免费高清在线观看日韩| 黑丝袜美女国产一区| 日韩视频一区二区在线观看| 免费女性裸体啪啪无遮挡网站| 精品久久久久久久毛片微露脸| 久久久国产精品麻豆| videosex国产| 黄色视频不卡| 90打野战视频偷拍视频| www.999成人在线观看| 亚洲熟妇中文字幕五十中出| 亚洲第一青青草原| 午夜免费观看网址| 国产av一区二区精品久久| av视频免费观看在线观看| 亚洲视频免费观看视频| 国产主播在线观看一区二区| 午夜福利一区二区在线看| 国产91精品成人一区二区三区| 国产av一区二区精品久久| 国产av一区二区精品久久| 亚洲精品久久成人aⅴ小说| 他把我摸到了高潮在线观看| av视频免费观看在线观看| 国产精品免费一区二区三区在线| 久久亚洲精品不卡| 久热这里只有精品99| 黄片小视频在线播放| 国产蜜桃级精品一区二区三区| 日韩精品免费视频一区二区三区| 精品人妻在线不人妻| 久久亚洲精品不卡| 国产精品,欧美在线| 99热只有精品国产| 亚洲中文av在线| 国产一区二区三区在线臀色熟女| 91av网站免费观看| 国产精品久久久久久人妻精品电影| 免费搜索国产男女视频| 一区二区三区精品91| 好男人在线观看高清免费视频 | 国产精品九九99| 19禁男女啪啪无遮挡网站| 成人亚洲精品一区在线观看| 黄色视频,在线免费观看| 亚洲一码二码三码区别大吗| 亚洲精华国产精华精| av视频免费观看在线观看| 一个人免费在线观看的高清视频| 国产黄a三级三级三级人| 午夜免费观看网址| 最近最新中文字幕大全电影3 | 亚洲性夜色夜夜综合| 日本免费a在线| 国产精品久久视频播放| 热99re8久久精品国产| 免费在线观看黄色视频的| 成人手机av| 亚洲一卡2卡3卡4卡5卡精品中文| 国产麻豆成人av免费视频| e午夜精品久久久久久久| 精品欧美一区二区三区在线| www.精华液| 亚洲国产中文字幕在线视频| 亚洲天堂国产精品一区在线| 黄色a级毛片大全视频| 国产激情欧美一区二区| 国产激情欧美一区二区| 人妻丰满熟妇av一区二区三区| 亚洲在线自拍视频| 国产亚洲精品一区二区www| 老熟妇乱子伦视频在线观看| 国产视频一区二区在线看| 久久婷婷成人综合色麻豆| 日本五十路高清| 日韩 欧美 亚洲 中文字幕| 日韩欧美一区视频在线观看| 久热这里只有精品99| 久久精品国产清高在天天线| 黄片小视频在线播放| 欧美日本中文国产一区发布| 淫秽高清视频在线观看| 久久精品国产亚洲av高清一级| 国产精品亚洲av一区麻豆| 久9热在线精品视频| 国产亚洲欧美98| av天堂久久9| 在线十欧美十亚洲十日本专区| 欧美乱色亚洲激情| 在线观看免费视频日本深夜| 婷婷精品国产亚洲av在线| 日韩成人在线观看一区二区三区| 久久久久久人人人人人| 嫩草影视91久久| 丁香欧美五月| 88av欧美| 国内毛片毛片毛片毛片毛片| 色播亚洲综合网| 波多野结衣一区麻豆| 亚洲人成伊人成综合网2020| www.精华液| 真人做人爱边吃奶动态| 又黄又爽又免费观看的视频| 国产精品免费视频内射| 亚洲成人久久性| 无遮挡黄片免费观看| 国产一卡二卡三卡精品| 久久久久久久午夜电影| 99国产精品一区二区蜜桃av| 久久香蕉激情| 99久久精品国产亚洲精品| 国产高清videossex| 麻豆一二三区av精品| 岛国在线观看网站| 一进一出抽搐gif免费好疼| 91成人精品电影| 久久精品国产清高在天天线| or卡值多少钱| 一级片免费观看大全| 久9热在线精品视频| 免费不卡黄色视频| 国产高清videossex| 精品久久久精品久久久| 精品少妇一区二区三区视频日本电影| 麻豆久久精品国产亚洲av| 午夜福利18| 国产欧美日韩精品亚洲av| 一夜夜www| 最近最新免费中文字幕在线| 69精品国产乱码久久久| 国产麻豆成人av免费视频| 多毛熟女@视频| 中文字幕久久专区| 成年版毛片免费区| ponron亚洲| 在线永久观看黄色视频| 亚洲中文av在线| 免费人成视频x8x8入口观看| 可以在线观看的亚洲视频| 久久久久久亚洲精品国产蜜桃av| 自拍欧美九色日韩亚洲蝌蚪91| 人人澡人人妻人| 欧美乱色亚洲激情| 亚洲成人久久性| 国产精品久久久人人做人人爽| 国产亚洲欧美在线一区二区| 一个人观看的视频www高清免费观看 | 精品一区二区三区四区五区乱码| 成熟少妇高潮喷水视频| 可以在线观看毛片的网站| 欧美性长视频在线观看| 纯流量卡能插随身wifi吗| 精品一品国产午夜福利视频| 亚洲av日韩精品久久久久久密| 一级,二级,三级黄色视频| 国产精品av久久久久免费| 狠狠狠狠99中文字幕| 成人免费观看视频高清| 欧美成人性av电影在线观看| 久久久国产成人免费| 精品久久久久久成人av| 99国产精品99久久久久| 亚洲欧美精品综合一区二区三区| 丝袜在线中文字幕| 欧美在线黄色| 男女床上黄色一级片免费看| 51午夜福利影视在线观看| 欧美日韩福利视频一区二区| 黄色丝袜av网址大全| 欧美 亚洲 国产 日韩一| 国产欧美日韩一区二区三区在线| 国产精品久久久久久精品电影 | 久久香蕉国产精品| 日韩av在线大香蕉| 在线观看免费午夜福利视频| 制服人妻中文乱码| 欧美乱色亚洲激情| 嫩草影视91久久| 18禁国产床啪视频网站| 99国产综合亚洲精品| 精品熟女少妇八av免费久了| 亚洲男人的天堂狠狠| 一本大道久久a久久精品| 老汉色∧v一级毛片| 日本 av在线| 国产av精品麻豆| 可以在线观看的亚洲视频| 久久国产精品人妻蜜桃| 成年版毛片免费区| 成人三级黄色视频| 久久精品人人爽人人爽视色| 免费看十八禁软件| 亚洲一区高清亚洲精品| 国产亚洲精品第一综合不卡| 91麻豆精品激情在线观看国产| 国产高清有码在线观看视频 | 亚洲国产欧美日韩在线播放| av天堂在线播放| 人人妻人人爽人人添夜夜欢视频| 最近最新中文字幕大全免费视频| 国产成人一区二区三区免费视频网站| 91老司机精品| 黄色成人免费大全| 国产又色又爽无遮挡免费看| 国产精品精品国产色婷婷| 久9热在线精品视频| 国产人伦9x9x在线观看| 亚洲av五月六月丁香网| 天天躁狠狠躁夜夜躁狠狠躁| 亚洲av成人av| 午夜精品在线福利| 欧美大码av| 国产亚洲av高清不卡| 欧美黑人精品巨大| 夜夜爽天天搞| 国产亚洲欧美精品永久| 国产亚洲精品一区二区www| 亚洲全国av大片| 国产成年人精品一区二区| 午夜免费激情av| 欧美久久黑人一区二区| 夜夜看夜夜爽夜夜摸| 欧美黑人精品巨大| 免费人成视频x8x8入口观看| 成人亚洲精品av一区二区| 岛国在线观看网站| 久久国产精品男人的天堂亚洲| 国产亚洲精品久久久久5区| 国产97色在线日韩免费| 国产1区2区3区精品| 亚洲精品国产区一区二| 日韩欧美三级三区| 久久天躁狠狠躁夜夜2o2o| 欧美成人免费av一区二区三区| 看黄色毛片网站| 男人舔女人的私密视频| 日韩三级视频一区二区三区| 在线观看免费日韩欧美大片| 国产aⅴ精品一区二区三区波| 侵犯人妻中文字幕一二三四区| 一区福利在线观看| 欧美成人性av电影在线观看| 国产亚洲欧美98| 熟妇人妻久久中文字幕3abv| 午夜福利18| 亚洲九九香蕉| 最新在线观看一区二区三区| 色播在线永久视频| 97碰自拍视频| 最近最新中文字幕大全电影3 | 久久性视频一级片| 午夜成年电影在线免费观看| 国产精品乱码一区二三区的特点 | 99香蕉大伊视频| 99精品在免费线老司机午夜| 夜夜看夜夜爽夜夜摸| 88av欧美| 日韩欧美免费精品| 国产av一区二区精品久久| 成年版毛片免费区| 亚洲午夜精品一区,二区,三区| 色哟哟哟哟哟哟| 十八禁网站免费在线| 国产熟女午夜一区二区三区| 丁香六月欧美| 国产高清视频在线播放一区| 深夜精品福利| 国产熟女午夜一区二区三区| 50天的宝宝边吃奶边哭怎么回事| 久久香蕉精品热| 久久天堂一区二区三区四区| 黄片大片在线免费观看| 高潮久久久久久久久久久不卡| 久久精品91蜜桃| 免费高清视频大片| av福利片在线| 欧美久久黑人一区二区| 亚洲专区国产一区二区| 美女大奶头视频| 一个人观看的视频www高清免费观看 | 欧美一级a爱片免费观看看 | 在线观看免费日韩欧美大片| 中文字幕久久专区| 午夜两性在线视频| 精品乱码久久久久久99久播| 电影成人av| 黄色丝袜av网址大全| 夜夜看夜夜爽夜夜摸| 变态另类丝袜制服| 午夜老司机福利片| 搞女人的毛片| 国产不卡一卡二| 久久久久国内视频| 高潮久久久久久久久久久不卡| 久久久久久人人人人人| 久久香蕉国产精品| 亚洲一区高清亚洲精品| 老熟妇乱子伦视频在线观看| 欧美激情 高清一区二区三区| 如日韩欧美国产精品一区二区三区| 91老司机精品| 男人舔女人的私密视频| 亚洲一码二码三码区别大吗| √禁漫天堂资源中文www| 亚洲精品在线美女| 亚洲av日韩精品久久久久久密| 国产成人欧美在线观看| 欧美绝顶高潮抽搐喷水| www.熟女人妻精品国产| 成年版毛片免费区| 国产精品久久久久久精品电影 | 久久午夜亚洲精品久久| 中文字幕av电影在线播放| 悠悠久久av| 国产精品九九99| 别揉我奶头~嗯~啊~动态视频| 最新美女视频免费是黄的| 老熟妇仑乱视频hdxx| 叶爱在线成人免费视频播放| 国产成人啪精品午夜网站| 身体一侧抽搐| 成在线人永久免费视频| 熟女少妇亚洲综合色aaa.| 国产精品99久久99久久久不卡| 91麻豆精品激情在线观看国产| 午夜精品久久久久久毛片777| 看免费av毛片| 国产成人系列免费观看| 视频在线观看一区二区三区| 真人做人爱边吃奶动态| 搡老岳熟女国产| 桃红色精品国产亚洲av| 久久国产亚洲av麻豆专区| 亚洲av成人不卡在线观看播放网| 制服丝袜大香蕉在线| 色综合欧美亚洲国产小说| 身体一侧抽搐| 少妇裸体淫交视频免费看高清 | 熟妇人妻久久中文字幕3abv| 亚洲片人在线观看| tocl精华| 91九色精品人成在线观看| 一a级毛片在线观看| tocl精华| 成人永久免费在线观看视频| 国产一卡二卡三卡精品| 黄色片一级片一级黄色片| 欧美不卡视频在线免费观看 | 校园春色视频在线观看| 亚洲午夜精品一区,二区,三区| 老汉色av国产亚洲站长工具| 极品人妻少妇av视频| 九色亚洲精品在线播放| 亚洲av成人av| 精品久久蜜臀av无| 国产一级毛片七仙女欲春2 | 亚洲第一青青草原| 99久久国产精品久久久| 在线十欧美十亚洲十日本专区| 婷婷六月久久综合丁香| 青草久久国产| 午夜福利影视在线免费观看| 欧美午夜高清在线| 欧美日韩福利视频一区二区| 在线十欧美十亚洲十日本专区| 国产91精品成人一区二区三区| x7x7x7水蜜桃| 亚洲电影在线观看av| 午夜福利免费观看在线| 亚洲国产中文字幕在线视频| 少妇粗大呻吟视频| av视频在线观看入口| 可以在线观看毛片的网站| 国产真人三级小视频在线观看| 欧美成狂野欧美在线观看| 咕卡用的链子| 国产私拍福利视频在线观看| 99在线视频只有这里精品首页| 亚洲专区字幕在线| 国产精品免费一区二区三区在线| 国产国语露脸激情在线看| 亚洲欧美精品综合一区二区三区| АⅤ资源中文在线天堂| 性欧美人与动物交配| 妹子高潮喷水视频| 日本免费a在线| 两个人看的免费小视频| 亚洲伊人色综图| 免费人成视频x8x8入口观看| 国产日韩一区二区三区精品不卡| 女人高潮潮喷娇喘18禁视频| 18禁裸乳无遮挡免费网站照片 | 国产亚洲欧美98| 久热爱精品视频在线9| or卡值多少钱| 亚洲第一电影网av| 91字幕亚洲| 日韩大码丰满熟妇| 在线观看舔阴道视频| 黄色女人牲交| 女人精品久久久久毛片| 亚洲 欧美 日韩 在线 免费| 亚洲人成77777在线视频| 亚洲欧洲精品一区二区精品久久久| av天堂在线播放| 国产精华一区二区三区| 亚洲一区二区三区不卡视频| 亚洲精品粉嫩美女一区| 成熟少妇高潮喷水视频| 18禁观看日本| 色精品久久人妻99蜜桃| 久久精品国产综合久久久| 精品乱码久久久久久99久播| www国产在线视频色| 国产高清视频在线播放一区| 久久亚洲真实| av电影中文网址| 19禁男女啪啪无遮挡网站| 日韩欧美在线二视频| 丝袜在线中文字幕| av超薄肉色丝袜交足视频| 国产亚洲精品一区二区www| 99国产精品免费福利视频| 精品午夜福利视频在线观看一区| ponron亚洲| www.www免费av| 午夜福利影视在线免费观看| 人人妻人人爽人人添夜夜欢视频| 欧美另类亚洲清纯唯美| 99国产极品粉嫩在线观看| 嫁个100分男人电影在线观看| 久久精品国产综合久久久| 天堂动漫精品| 多毛熟女@视频| 日韩精品青青久久久久久| 成年人黄色毛片网站| 亚洲欧美精品综合一区二区三区| 黄色视频,在线免费观看| 50天的宝宝边吃奶边哭怎么回事| 日韩精品免费视频一区二区三区| 国产精品秋霞免费鲁丝片| 成人特级黄色片久久久久久久| 国产精品久久久久久精品电影 | 国产亚洲精品久久久久5区| 最新美女视频免费是黄的| 美女免费视频网站| 国产97色在线日韩免费| 成人特级黄色片久久久久久久| 国产高清有码在线观看视频 | 亚洲第一青青草原| 欧美成人免费av一区二区三区| 精品电影一区二区在线| 久久久久九九精品影院| 曰老女人黄片| 99国产综合亚洲精品| 免费一级毛片在线播放高清视频 | 国产精品永久免费网站| 人人妻人人澡欧美一区二区 | 黄色 视频免费看| a级毛片在线看网站| 成人永久免费在线观看视频| 亚洲精品国产精品久久久不卡| 高清在线国产一区| 啦啦啦免费观看视频1| av片东京热男人的天堂| 97人妻天天添夜夜摸| www.999成人在线观看| 国产片内射在线| 国产三级在线视频| 一个人观看的视频www高清免费观看 | 一区二区三区精品91| 色老头精品视频在线观看| 国产亚洲精品久久久久5区| 国产亚洲精品一区二区www| 中文字幕人妻丝袜一区二区| 日韩欧美国产在线观看| 国产一区在线观看成人免费| 欧美中文日本在线观看视频| 乱人伦中国视频| 大香蕉久久成人网| 国产精品一区二区精品视频观看| 制服丝袜大香蕉在线| 精品久久久精品久久久| 亚洲九九香蕉| 国产成+人综合+亚洲专区| 亚洲无线在线观看| 一级毛片精品| 一二三四社区在线视频社区8| 久久午夜综合久久蜜桃| 免费av毛片视频| 欧美日韩亚洲国产一区二区在线观看| av天堂在线播放| 一进一出抽搐动态| 不卡一级毛片| 男人的好看免费观看在线视频 | 国产国语露脸激情在线看| 悠悠久久av| 后天国语完整版免费观看| 国产视频一区二区在线看| 丝袜人妻中文字幕| 侵犯人妻中文字幕一二三四区| 一级,二级,三级黄色视频| 老熟妇乱子伦视频在线观看| 欧美日韩乱码在线| 日日夜夜操网爽| 91精品三级在线观看| 国产aⅴ精品一区二区三区波| 久久精品国产亚洲av香蕉五月| 自拍欧美九色日韩亚洲蝌蚪91| 成人三级黄色视频| 性欧美人与动物交配| 91成人精品电影| 日本vs欧美在线观看视频| 久久欧美精品欧美久久欧美| x7x7x7水蜜桃| 乱人伦中国视频| bbb黄色大片| 国产高清视频在线播放一区| 如日韩欧美国产精品一区二区三区| 欧美亚洲日本最大视频资源| 一本久久中文字幕| 日本黄色视频三级网站网址| 一区二区三区精品91| 亚洲熟女毛片儿| 成人手机av| 久久婷婷成人综合色麻豆| 真人一进一出gif抽搐免费| 亚洲精品在线美女| 久久性视频一级片| 亚洲成人免费电影在线观看| 青草久久国产| 亚洲精品国产区一区二| tocl精华| 国产成人欧美| 中文字幕人妻熟女乱码| 伊人久久大香线蕉亚洲五| 精品国产一区二区久久| 国产精品影院久久| 国产亚洲欧美98| 搡老岳熟女国产| 欧美成人免费av一区二区三区| 日韩 欧美 亚洲 中文字幕| 成人亚洲精品av一区二区| 国产主播在线观看一区二区| 国产人伦9x9x在线观看| 99热只有精品国产| 黄色a级毛片大全视频| 男女床上黄色一级片免费看| 50天的宝宝边吃奶边哭怎么回事| 天堂√8在线中文| 丁香六月欧美| 久久精品人人爽人人爽视色| 搡老熟女国产l中国老女人| 免费女性裸体啪啪无遮挡网站| 天天一区二区日本电影三级 | 久久精品国产综合久久久| 国产伦人伦偷精品视频| 岛国在线观看网站| 亚洲国产精品成人综合色| 黄色成人免费大全| 国产精华一区二区三区| 每晚都被弄得嗷嗷叫到高潮| 久99久视频精品免费| 乱人伦中国视频| 在线av久久热| avwww免费| 国产日韩一区二区三区精品不卡| 亚洲熟妇中文字幕五十中出| 精品久久久久久久人妻蜜臀av | 成人国语在线视频| 中文字幕人成人乱码亚洲影| 99久久综合精品五月天人人| 婷婷六月久久综合丁香| 人人澡人人妻人| 变态另类丝袜制服| 国产成人精品久久二区二区免费| 91av网站免费观看| 久久久久国产精品人妻aⅴ院| 老鸭窝网址在线观看| 黄网站色视频无遮挡免费观看| 久99久视频精品免费| 人人妻人人澡欧美一区二区 | 一a级毛片在线观看| 国产片内射在线| 十八禁网站免费在线| 久久国产亚洲av麻豆专区| 久久中文字幕一级| www日本在线高清视频| 国产精品 国内视频| 亚洲电影在线观看av| 成人手机av| 欧美+亚洲+日韩+国产| 操出白浆在线播放| 午夜影院日韩av| 校园春色视频在线观看| 免费在线观看完整版高清| 日日夜夜操网爽| 国产精品av久久久久免费| 97人妻天天添夜夜摸| 国产精华一区二区三区| 自线自在国产av| 大码成人一级视频| 国产免费av片在线观看野外av| 久久人妻av系列| 亚洲av日韩精品久久久久久密| 亚洲中文日韩欧美视频| 最近最新中文字幕大全免费视频| 精品不卡国产一区二区三区| 亚洲一卡2卡3卡4卡5卡精品中文| 婷婷精品国产亚洲av在线|